The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells

Area of Science:

• Oncology
• Immunology

Background:

• Cancer stem-like cells (CSC) are crucial drivers of tumor growth and metastasis.
• Targeting CSC is a key strategy in developing effective cancer therapies.
• Chemokine receptors CXCR1 and CXCR2 play roles in tumor progression and immune cell recruitment.

Purpose of the Study:

• To review preclinical and clinical findings on targeting CXCR1 and CXCR2 in breast cancer.
• To evaluate the therapeutic potential of CXCR1/CXCR2 inhibition in breast cancer stem-like cells.

Main Methods:

• Review of preclinical studies investigating CXCR1/CXCR2 inhibition in breast cancer models.
• Analysis of clinical trial data, including a phase 2 randomized, double-blind study.
• Focus on the impact of CXCR1/CXCR2 interference on cancer stem-like cells.

Main Results:

• Preclinical data suggest that blocking CXCR1 and CXCR2 can inhibit breast cancer stem-like cell activity.
• Clinical investigations are ongoing, with a phase 2 trial evaluating this strategy in breast cancer patients.
• Interference with CXCR1/CXCR2 demonstrates potential for targeting therapy-resistant CSC.

Conclusions:

• Targeting chemokine receptors CXCR1 and CXCR2 represents a promising therapeutic avenue for breast cancer, particularly for eliminating cancer stem-like cells.
• Further clinical evaluation is warranted to confirm the efficacy and safety of CXCR1/CXCR2 inhibition in breast cancer treatment.
• This strategy holds potential for overcoming treatment resistance associated with cancer stem-like cells.